MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

NCT03089645 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: MEDI5083 monotherapy
BIOLOGICAL: MEID5083 with Durvalumab or Tremelimumab
BIOLOGICAL: Medi5083 with Durvalumab and Docetaxel

Sponsor

MedImmune LLC